How the SLC16A11 gene variant affects metformin in type 2 diabetes
Compares metformin response in adults with type 2 diabetes, with or without SLC16A11 variant.
Plain-language title generated from the registry record
Registry title: Metformin Effects According to SLC16A11 Carrier Status
Key facts
- Where
- Mexico City, MexicoSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07760883, who can take part
Where in Mexico
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico City, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Trial code
- NCT07760883
- Record updated
- 12 August 2026
- Original description
This prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformin titrated to the maximum tolerated dose, between 1,500 and 2,250 mg/day. The primary outcome is the change in glycated hemoglobin, with additional assessment of seven-point capillary glucose profiles, liver enzymes, visceral fat, lipid profile, and lactate concentrations. The study plans to include 154 participants to compare treatment response between both genetic groups and explore the potential value of a more personalized therapeutic approach.Read full original descriptionShow less
Effect of Metformin in Individuals With Type 2 Diabetes According to SLC16A11 Risk Variant Carrier Status
This prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformin titrated to the maximum tolerated dose, between 1,500 and 2,250 mg/day. The primary outcome is the change in glycated hemoglobin, with additional assessment of seven-point capillary glucose profiles, liver enzymes, visceral fat, lipid profile, and lactate concentrations. The study plans to include 154 participants to compare treatment response between both genetic groups and explore the potential value of a more personalized therapeutic approach.
Inclusion: Male and female participants; Aged 18 to 65 years; Diagnosis of type 2 diabetes; Estimated glomerular filtration rate (eGFR) >60 mL/min; Glycated hemoglobin (HbA1c) ≤8%; Participants who are treatment-naïve, receiving metformin monotherapy, or receiving dual glucose-lowering therapy; Participants who agree to take part in the study.
Exclusion: Participants receiving insulin therapy; Concurrent participation in another research study; Chronic conditions such as HIV infection, cancer, or rheumatologic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA); Participants receiving treatment with three glucose-lowering medications; Pregnancy; Breastfeeding; Body mass index (BMI) ≥45 kg/m².